"Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in OSA"
NCT ID: NCT02348606
Last Updated: 2019-07-23
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
476 participants
INTERVENTIONAL
2015-05-31
2016-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
"Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in Narcolepsy"
NCT02348593
"A Long-Term Safety Study of JZP-110 in the Treatment of Excessive Sleepiness in Subjects With Narcolepsy or OSA"
NCT02348632
Study Assessing Effects of JZP-110 on Driving Performance in the Treatment of Excessive Sleepiness in OSA
NCT02806895
A Multicenter Study of the Efficacy and Safety of JZP-258 in the Treatment of Idiopathic Hypersomnia (IH) With an Open-label Safety Extension
NCT03533114
A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JZP441 in Healthy Participants
NCT05720494
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
37.5 mg of JZP-110
Once Daily Dosing
JZP-110
75 mg of JZP-110
Once Daily Dosing
JZP-110
150 mg of JZP-110
Once Daily Dosing
JZP-110
300 mg of JZP-110
Once Daily Dosing
JZP-110
Placebo
Once Daily Dosing
Placebo oral tablet
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
JZP-110
Placebo oral tablet
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Diagnosis of OSA according to ICSD-3 criteria
3. Body mass index from 18 to \<45 kg/m2
4. Consent to use a medically acceptable method of contraception
5. Willing and able to provide written informed consent
Exclusion Criteria
2. Any other clinically relevant medical, behavioral, or psychiatric disorder other than OSA that is associated with excessive sleepiness
3. History or presence of bipolar disorder, bipolar related disorders, schizophrenia, schizophrenia spectrum disorders, or other psychotic disorders according to DSM-5 criteria
4. History or presence of any acutely unstable medical condition, behavioral or psychiatric disorder (including active suicidal ideation), or surgical history that could affect the safety of the subject or interfere with study efficacy, safety, PK assessments, or the ability of the subject to complete the trial per the judgment of the Investigator.
5. History of bariatric surgery within the past year or a history of any gastric bypass procedure
6. Presence or history of significant cardiovascular disease
7. Use of any over-the-counter (OTC) or prescription medications that could affect the evaluation of excessive sleepiness
8. Received an investigational drug in the past 30 days or five half-lives
9. Previous exposure to or participation in a clinical trial of JZP-110 (ADX-N05, R228060, or YKP10A)
10. History of phenylketonuria (PKU) or history of hypersensitivity to phenylalanine-derived products
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Jazz Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pulmonary Associates
Glendale, Arizona, United States
Mayo Clinic in Arizona
Scottsdale, Arizona, United States
Preferred Research Partners
Little Rock, Arkansas, United States
UC San Diego Medical Center
La Jolla, California, United States
So Cal Institute For Respiratory Diseases, Inc.
Los Angeles, California, United States
Pacific Sleep Medicine
Oceanside, California, United States
Stanford University Center for Narcolepsy
Redwood City, California, United States
Pacific Research Network, Inc.
San Diego, California, United States
PAB Clinical Research
Brandon, Florida, United States
MD Clinical
Hallandale, Florida, United States
Clinical Research Group of St. Petersburg
St. Petersburg, Florida, United States
Florida Pediatric Research Institute
Winter Park, Florida, United States
NeuroTrials Research Inc.
Atlanta, Georgia, United States
SleepMed of Central Georgia
Macon, Georgia, United States
Northwestern University Feinberg School of Medicine
Chicago, Illinois, United States
University of Illinois at Chicago College of Nursing
Chicago, Illinois, United States
Kentucky Research Group
Louisville, Kentucky, United States
Johns Hopkins Hospital
Baltimore, Maryland, United States
The Center for Sleep & Wake Disorders
Chevy Chase, Maryland, United States
Neurocare, Inc.
Newton, Massachusetts, United States
Henry Ford Hospital Sleep Disorders & Research Center
Detroit, Michigan, United States
Clinical Neurophysiology Services
Sterling Heights, Michigan, United States
Minnesota Lung Center
Edina, Minnesota, United States
Sleep Medicine & Research Center, St. Luke's Hospital
Chesterfield, Missouri, United States
University of Missouri
Columbia, Missouri, United States
Clayton Sleep Institute
St Louis, Missouri, United States
Clinilabs
New York, New York, United States
Montefiore Medical Center
The Bronx, New York, United States
Duke University Medical Center
Durham, North Carolina, United States
Hickory Research Center
Hickory, North Carolina, United States
Hickory Research Center, ARSM Research, LLC
Huntersville, North Carolina, United States
Raleigh Neurology Associates
Raleigh, North Carolina, United States
Northcoast Clinical Trials Inc.
Beachwood, Ohio, United States
Sleep Management Institute
Cincinnati, Ohio, United States
CTI Clinical Research Center
Cincinnati, Ohio, United States
Case Western Reserve University
Cleveland, Ohio, United States
Southwest Cleveland Sleep Research Center
Cleveland, Ohio, United States
Cleveland Clinic
Cleveland, Ohio, United States
Ohio Sleep Medicine & Neuroscience Institute
Dublin, Ohio, United States
Mercy St. Anne & Mercy St. Charles Sleep Disorders Center
Toledo, Ohio, United States
Sleep Med of South Carolina
Columbia, South Carolina, United States
FutureSearch Trials of Neurology LP
Austin, Texas, United States
Todd J. Swick
Houston, Texas, United States
Sleep Therapy & Research Center
San Antonio, Texas, United States
Swedish Medical Center
Seattle, Washington, United States
London Health Sciences Centre
London, Ontario, Canada
Niagra Clinical Research
Niagra Falls, Ontario, Canada
Toronto Sleep Institute
Toronto, Ontario, Canada
Toronto Psychiatric Research Foundation
Toronto, Ontario, Canada
Pediatric Sleep Research Inc.
Toronto, Ontario, Canada
Hospital Roger Salengro
Lille, , France
Universite Paris 5 Hôtel-Dieu
Paris, , France
Hopital Bichat - Claude Bernard
Paris, , France
medbo Bezirksklinikum Regensburg Schlafmedizinisches Zentrum
Regensburg, Bavaria, Germany
Universitätsklinikum Münster Department für Neurologie
Münster, North Rhine-Westphalia, Germany
Advanced Sleep Research GmbH
Berlin, , Germany
Studienzentrum Wilhelmshoehe
Kassel, , Germany
Somni bene GmbH Institut für Medizinische Forschung und Schlafmedizin Schwerin GmbH
Schwerin, , Germany
Sleep Wake Center SEIN Heemstede
Heemsteded, North Holland, Netherlands
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Rosenberg R, Thorpy MJ, Dauvilliers Y, Schweitzer PK, Zammit G, Gotfried M, Bujanover S, Scheckner B, Malhotra A. Incidence and duration of common early-onset adverse events in randomized controlled trials of solriamfetol for treatment of excessive daytime sleepiness in obstructive sleep apnea and narcolepsy. J Clin Sleep Med. 2022 Jan 1;18(1):235-244. doi: 10.5664/jcsm.9550.
Schweitzer PK, Mayer G, Rosenberg R, Malhotra A, Zammit GK, Gotfried M, Chandler P, Baladi M, Strohl KP. Randomized Controlled Trial of Solriamfetol for Excessive Daytime Sleepiness in OSA: An Analysis of Subgroups Adherent or Nonadherent to OSA Treatment. Chest. 2021 Jul;160(1):307-318. doi: 10.1016/j.chest.2021.02.033. Epub 2021 Feb 22.
Weaver TE, Menno DM, Bron M, Crosby RD, Morris S, Mathias SD. Determination of thresholds for minimally important difference and clinically important response on the functional outcomes of sleep questionnaire short version in adults with narcolepsy or obstructive sleep apnea. Sleep Breath. 2021 Sep;25(3):1707-1715. doi: 10.1007/s11325-020-02270-3. Epub 2021 Jan 4.
Rosenberg R, Baladi M, Bron M. Clinically relevant effects of solriamfetol on excessive daytime sleepiness: a posthoc analysis of the magnitude of change in clinical trials in adults with narcolepsy or obstructive sleep apnea. J Clin Sleep Med. 2021 Apr 1;17(4):711-717. doi: 10.5664/jcsm.9006.
Weaver TE, Drake CL, Benes H, Stern T, Maynard J, Thein SG, Andry JM Sr, Hudson JD, Chen D, Carter LP, Bron M, Lee L, Black J, Bogan RK. Effects of Solriamfetol on Quality-of-Life Measures from a 12-Week Phase 3 Randomized Controlled Trial. Ann Am Thorac Soc. 2020 Aug;17(8):998-1007. doi: 10.1513/AnnalsATS.202002-136OC.
Schweitzer PK, Rosenberg R, Zammit GK, Gotfried M, Chen D, Carter LP, Wang H, Lu Y, Black J, Malhotra A, Strohl KP; TONES 3 Study Investigators. Solriamfetol for Excessive Sleepiness in Obstructive Sleep Apnea (TONES 3). A Randomized Controlled Trial. Am J Respir Crit Care Med. 2019 Jun 1;199(11):1421-1431. doi: 10.1164/rccm.201806-1100OC.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
14-003
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.